RetinalGenix Technologies Inc. Advances in Gene Editing for Retinal Diseases

RetinalGenix Technologies Inc., a biotechnology company based in the United States, is making significant strides in the field of gene editing to develop innovative treatments for inherited retinal diseases. Listed on the OTC Bulletin Board, the company is dedicated to transforming the lives of individuals affected by these conditions through potential breakthrough therapies.

As of May 12, 2025, RetinalGenix Technologies Inc. closed at a price of $5.02 per share. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of $6.36 on January 13, 2025, and a low of $0.0001 on January 2, 2025. The current market capitalization stands at approximately $92,981,945 USD.

RetinalGenix Technologies Inc. is focused on leveraging gene editing technologies to address inherited retinal diseases, which are a group of genetic disorders that can lead to vision loss or blindness. The company’s mission is to provide hope and potential cures for those affected by these debilitating conditions.

The biotechnology sector continues to watch RetinalGenix Technologies Inc. closely as it progresses in its research and development efforts. The company’s commitment to innovation and its focus on gene editing technologies position it as a key player in the quest to develop effective treatments for inherited retinal diseases.

For more information on RetinalGenix Technologies Inc. and its ongoing projects, stakeholders and interested parties are encouraged to follow updates from the company and the OTC Bulletin Board.